Henry Schein to Report Q2 Earnings: What's in Store for the Stock?

Henry Schein (HSIC) is anticipated to report second-quarter earnings with Zacks Consensus Estimates projecting revenues of $3.22 billion (+2.7% YoY) and EPS of $1.18 (-4.1% YoY), the latter having seen a recent 1-cent downward revision. Despite the projected EPS decline, the company, which has historically beaten estimates in three of the last four quarters, carries a Zacks Rank #3 and a positive Earnings ESP of +2.37%, indicating a higher probability of surpassing expectations. Underlying segment analysis suggests stable conditions in dental and medical markets, benefits from the TriMed acquisition, and growth in cloud-based technology solutions, though the orthodontic business and practice transitions may face headwinds.

Analysis

Henry Schein (HSIC) approaches its second-quarter earnings report with a mixed but cautiously optimistic outlook. Consensus estimates project revenue of $3.22 billion, a 2.7% year-over-year increase, but an adjusted EPS of $1.18, representing a 4.1% decline from the prior year. This EPS estimate has also seen a slight downward revision in the last 30 days. Despite the projected earnings contraction, the company's positive Earnings ESP of +2.37% combined with a history of surpassing estimates in three of the last four quarters (averaging a 2.4% surprise) suggests a strong probability of an earnings beat. Segment analysis reveals a nuanced picture: the core Global Distribution and Value-Added Services segment is expected to see muted revenue growth of just 0.3%, hindered by softness in France and a fluctuating practice transitions business, which largely offsets stable US dental/medical markets and potential market share gains. Growth is more pronounced in the Global Specialty Products and Global Technology segments, projected to grow 2.0% and 2.4% respectively. This growth is driven by the recent TriMed acquisition, robust European implant sales, the resolution of a key product supply-chain issue, and increased adoption of cloud-based software, though partially offset by a reorganization in the orthodontic business.

Key Decisions for Investors

• Given the positive Earnings ESP of +2.37%, investors should consider the high probability of an EPS beat relative to the consensus estimate of $1.18, which could act as a short-term positive catalyst for the stock.
• Look beyond the headline numbers in the earnings release to scrutinize segment-level performance and margins; specifically, assess if growth from the TriMed acquisition and cloud software adoption can meaningfully offset the sluggish 0.3% projected growth in the core distribution segment.
• Pay close attention to management's forward-looking guidance, as commentary on the orthodontic business reorganization and the trajectory of dental equipment demand will be critical for evaluating the sustainability of growth and potential for margin recovery beyond Q2.